| Ytd | 31.77% | |
| 1y | 133.72% |
| Open | 244.77 | Prev Close | 244.77 | Low | 237.64 | High | 247.64 | Mkt Cap | 12.38B |
| Vol | 757.95K | Avg Vol | 898.99K | EPS | -3.73 | P/E | N/A | Forward P/E | 40.81 |
| Beta | 0.60 | Short Ratio | 4.99 | Inst. Own | 76.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 227.38 | 200-d Avg | 172.83 | 1yr Est | 276.47 |
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu
TD Cowen analyst Joseph Thome maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises t
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm
Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in t
Health officials explored restricting specific antidepressants among SSRI drugs-sources
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weigh
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform
Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweigh
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform an
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raise
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) wi
Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af
Axsome (AXSM) Q1: Revenue beats, but wider loss and rising expenses weigh on shares. Get the key dat
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) wi
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.26) per share which missed the an
Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p
FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for a
UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p
Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin
Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturi
PPL Corporation (NYSE:PPL) announced it plans to sell 20,000,000 equity units in a public offering.
William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-51
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. l
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent ge
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe